19 results on '"Poonja A"'
Search Results
2. Abstract B010: Dynamics of fibril collagen remodeling in early DCIS invasions: integrating in silico modeling and tumor histology
- Author
-
Katarzyna A. Rejniak, Sharan Poonja, Shreya Mathur, Mehdi Damaghi, and Marilyn Bui
- Subjects
Cancer Research ,Oncology - Abstract
Progression from a ductal carcinoma in situ (DCIS) to an invasive ductal carcinoma (IDC) involves changes in the surrounding extracellular matrix (ECM) fibril patterns before and during the development of ductal microinvasions, i.e., small cohorts of tumor cells that breach the duct and migrate through the stroma. We used a combination of mathematical modeling (with the hybrid agent-based model silicoDCIS) and advanced image analysis techniques applied to histological and fluorescent images in order to identify the rules of cell-ECM interactions that guide the emergence of various alignment patterns of the ECM fibrils. This includes the three tumor associated collagen signatures (TACS) previously observed in laboratory experiments. This integrated approach provides an in silico tool for testing biomechanical hypotheses of tumor cell-tumor matrix interactions. These findings can be compared to the patient histology samples and may help to define criteria for identification of DCIS to IDC transition and future development of new diagnostic methods. Citation Format: Katarzyna A. Rejniak, Sharan Poonja, Shreya Mathur, Mehdi Damaghi, Marilyn Bui. Dynamics of fibril collagen remodeling in early DCIS invasions: integrating in silico modeling and tumor histology [abstract]. In: Proceedings of the AACR Special Conference on Rethinking DCIS: An Opportunity for Prevention?; 2022 Sep 8-11; Philadelphia, PA. Philadelphia (PA): AACR; Can Prev Res 2022;15(12 Suppl_1): Abstract nr B010. more...
- Published
- 2022
- Full Text
- View/download PDF
Catalog
3. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice
- Author
-
David Fenton, Ashley T. Freeman, Zia Poonja, Elaine S. Wai, G. Geller, Doran Ksienski, E. Brooks, Sarah Irons, Mary Lesperance, Nicole S. Croteau, Angela Chan, and Leathia Fiorino
- Subjects
Adult ,Male ,Rural Population ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Drug-Related Side Effects and Adverse Reactions ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,law.invention ,Cohort Studies ,03 medical and health sciences ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Randomized controlled trial ,law ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Humans ,Medicine ,Karnofsky Performance Status ,Adverse effect ,Aged ,Neoplasm Staging ,Aged, 80 and over ,business.industry ,Cancer ,Pneumonia ,Middle Aged ,medicine.disease ,Survival Analysis ,Clinical trial ,Clinical Practice ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cohort ,Female ,Non small cell ,business - Abstract
While pembrolizumab improves overall survival (OS) in a subset of advanced nonsmall cell lung cancer (aNSCLC) patients (pts) in clinical trials, individuals with poor Eastern Cooperative Oncology Group performance status (ECOG PS) were excluded. Furthermore, some studies have identified a potential link between improved pt outcomes and development of immune related adverse events (irAE.) In a large provincial cohort, we studied the efficacy and safety of pembrolizumab for poor ECOG PS pts and whether irAE correlate with improved OS.aNSCLC pts treated with pembrolizumab between 06/2015 and 08/2018 at BC Cancer were retrospectively identified. Kaplan-Meier curves of OS from initiation of pembrolizumab were plotted. 3-, 6-, and 9- month landmark Kaplan-Meier analysis was performed and log-rank tests used to determine an association of irAE subtypes with OS. Multivariable logistic regression identified variables associated with grade ≥3 irAE within 3 months of pembrolizumab initiation.Of 190 pts, 74.2% were treatment naïve and 92.6% had PD-L1 expression ≥ 50%. Median OS in the 1st line and ≥2nd line settings were 24.3 months (95% CI, 9.7-not reached, NR) and 13.4 months (95% CI, 8.1-NR), respectively. Pts with ECOG PS 2/3 had lower median OS than if ECOG PS 0/1 (5.8 months vs. 16.7 months, p 0.0001). In multivariable analysis, the odds of grade ≥ 3 irAE within 3 months was 6.3 fold higher if ECOG PS 2/3 versus 0/1 (p = 0.05). Development of pneumonitis at the 9 month landmark weakly correlated with decreased OS (p = 0.09).In the studied cohort, ECOG PS 2/3 pts had a significantly lower OS and greater odds of experiencing high-grade irAE than if ECOG PS 0/1. Development of irAE did not result in improved OS. Randomized trials to determine benefit of pembrolizumab for poor ECOG PS pts are needed. more...
- Published
- 2019
- Full Text
- View/download PDF
4. Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer
- Author
-
Charles Butts, Mustapha Tehfe, Barbara Melosky, Randeep Sangha, Z. Poonja, Z. Xu, A.M.Y. Chan, Rosalyn A. Juergens, Normand Blais, Ming-Sound Tsao, Jason Agulnik, Vera Hirsh, Paul B. Card, D.G. Bebb, G. Liu, Ronald L. Burkes, Roula Albadine, Parneet Cheema, Diana N. Ionescu, W. Morzycki, and Mark Vincent more...
- Subjects
0301 basic medicine ,Oncology ,Alectinib ,medicine.medical_specialty ,Brigatinib ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,tyrosine kinase inhibitors ,Medicine ,Anaplastic lymphoma kinase ,cns ,metastases ,Lung cancer ,tkis ,Ceritinib ,Crizotinib ,business.industry ,anaplastic lymphoma kinase ,medicine.disease ,Lorlatinib ,030104 developmental biology ,Pemetrexed ,ALK ,030220 oncology & carcinogenesis ,business ,Non-small-cell lung cancer ,nsclc ,medicine.drug - Abstract
Inhibition of the anaplastic lymphoma kinase (alk) oncogenic driver in advanced non-small-cell lung carcinoma (nsclc) improves survival. In 2015, Canadian thoracic oncology specialists published a consensus guideline about the identification and treatment of ALK-positive patients, recommending use of the alk inhibitor crizotinib in the first line. New scientific literature warrants a consensus update. Clinical trials of alk inhibitor were reviewed to assess benefits, risks, and implications relative to current Canadian guidance in patients with ALK-positive nsclc. Randomized phase iii trials have demonstrated clinical benefit for single-agent alectinib and ceritinib used in treatment-naï, ve patients and as second-line therapy after crizotinib. Phase ii trials have demonstrated activity for single-agent brigatinib and lorlatinib in further lines of therapy. Improved responses in brain metastases were observed for all second- and next/third-generation alk tyrosine kinase inhibitors in patients progressing on crizotinib. Canadian recommendations are therefore revised as follows: Multiple lines of alk inhibition are now recommended for patients with advanced nsclc with an ALK rearrangement. more...
- Published
- 2018
- Full Text
- View/download PDF
5. Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab
- Author
-
Nicole S. Croteau, Leathia Fiorino, Tiffany Patterson, Mary Lesperance, David Fenton, Angela Chan, Sarah Irons, Elaine S. Wai, Ashley T. Freeman, Zia Poonja, and Doran Ksienski
- Subjects
Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Programmed Cell Death 1 Receptor ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,03 medical and health sciences ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,030212 general & internal medicine ,Adverse effect ,Immune Checkpoint Inhibitors ,Survival analysis ,Retrospective Studies ,business.industry ,Age Factors ,Cancer ,Retrospective cohort study ,medicine.disease ,Clinical trial ,Nivolumab ,030220 oncology & carcinogenesis ,Cohort ,Geriatrics and Gerontology ,business - Abstract
Objectives To explore the association of age with development of immune related adverse events (irAE) and survival in patients with advanced nonsmall cell lung cancer (aNSCLC) receiving programmed cell death 1 antibodies (PD-1 Ab) outside of clinical trials. Methods A multicenter retrospective study of PD-1 Ab prescription for patients with aNSCLC between 06/2015–11/2018 at BC Cancer. Multivariable (MVA) logistic regression identified baseline variables associated with irAE manifested within 3 months of PD-1 Ab initiation. Overall survival (OS) analyzed in a propensity-score matched cohort and survival outcomes compared between age groups by stratified log-rank. Six-week landmark analysis was performed and OS compared between patients with interrupted versus continuous treatment by log-rank. Results Of 527 patients, 40.6% were age ≤ 64 years, 40.6% were 65–74 years, and 18.8% were ≥ 75 years. In MVA, ECOG performance status 2/3 (p = .034), squamous histology (p = .031), and nivolumab therapy (vs. pembrolizumab, p = .012) were associated with increased odds of irAE by 3 months of treatment. Across age groups no difference existed in any grade irAE (p = .98), hospitalization (p = 1.0), or corticosteroids use (p = .51). The propensity score–matched survival analysis comprised 77 patients from each age group; all covariates were balanced. OS did not differ significantly by age in the matched cohort (p = .17). Treatment interruption due to irAE at 6 weeks was more common in patient ≥75 years (vs. Conclusion In this cohort of patients with aNSCLC treated in routine clinical practice with PD-1 Ab, immune-toxicity and observed survival were similar amongst age groups. more...
- Published
- 2019
6. Morphophenotypic classification of tumor organoids as an indicator of drug exposure and penetration potential
- Author
-
Sharan Poonja, Katarzyna A. Rejniak, and Aleksandra Karolak
- Subjects
0301 basic medicine ,Cell division ,Cell ,Cancer Treatment ,0302 clinical medicine ,Neoplasms ,Medicine and Health Sciences ,Tumor Cells, Cultured ,Tumor Microenvironment ,Cell Cycle and Cell Division ,Biology (General) ,Organ Cultures ,Materials ,Ecology ,Pharmaceutics ,Simulation and Modeling ,Phenotype ,3. Good health ,Cell biology ,Organoids ,medicine.anatomical_structure ,Computational Theory and Mathematics ,Oncology ,Cell Processes ,Modeling and Simulation ,Physical Sciences ,Disease Progression ,Biological Cultures ,Research Article ,QH301-705.5 ,Surface Properties ,Materials Science ,Geometry ,Antineoplastic Agents ,Biology ,Research and Analysis Methods ,Models, Biological ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Imaging, Three-Dimensional ,Drug Therapy ,In vivo ,Adhesives ,Genetics ,Organoid ,medicine ,Humans ,Computer Simulation ,Epigenetics ,Molecular Biology ,Cell Cycle Inhibitors ,Ecology, Evolution, Behavior and Systematics ,Mathematical Modeling ,Contact inhibition ,Biology and Life Sciences ,Computational Biology ,Cell Biology ,030104 developmental biology ,Radii ,Tumor progression ,Drug Screening Assays, Antitumor ,030217 neurology & neurosurgery ,Mathematics - Abstract
The dynamics of tumor progression is driven by multiple factors, which can be exogenous to the tumor (microenvironment) or intrinsic (genetic, epigenetic or due to intercellular interactions). While tumor heterogeneity has been extensively studied on the level of cell genetic profiles or cellular composition, tumor morphological diversity has not been given as much attention. The limited analysis of tumor morphophenotypes may be attributed to the lack of accurate models, both experimental and computational, capable of capturing changes in tumor morphology with fine levels of spatial detail. Using a three-dimensional, agent-based, lattice-free computational model, we generated a library of multicellular tumor organoids, the experimental analogues of in vivo tumors. By varying three biologically relevant parameters—cell radius, cell division age and cell sensitivity to contact inhibition, we showed that tumor organoids with similar growth dynamics can express distinct morphologies and possess diverse cellular compositions. Taking advantage of the high-resolution of computational modeling, we applied the quantitative measures of compactness and accessible surface area, concepts that originated from the structural biology of proteins. Based on these analyses, we demonstrated that tumor organoids with similar sizes may differ in features associated with drug effectiveness, such as potential exposure to the drug or the extent of drug penetration. Both these characteristics might lead to major differences in tumor organoid’s response to therapy. This indicates that therapeutic protocols should not be based solely on tumor size, but take into account additional tumor features, such as their morphology or cellular packing density., Author summary Primary tumors and tumor metastases grow as three-dimensional (3D) masses of cells. Depending on the surrounding stroma, they may acquire various shapes, more or less irregular. Tumor organoids are the 3D experimental cultures that mimic growth of in vivo tumors, as well as their response to treatments. However, it is difficult to assess experimentally in a reproducible and quantitative way, how tumor morphology influences treatment efficacy. Here, we used mathematical modeling and computer simulations to analyze the structure of the simulated organoids and to classify them with regards to two quantitative features: the tumor accessible surface area (ASA) describing organoid exposure to the drug and the extent of drug penetration through the tumor tissue (organoid compactness). We showed that organoids of similar sizes and growth dynamics can, in fact, be characterized by distinct values of compactness and ASA, and thus may respond differently to the drug treatment. We suggest that these tumor features should be taken into consideration in addition to tumor size, when the therapeutic interventions are designed. more...
- Published
- 2019
7. Abstract A47: In silico organoids: A model for deconvolution of microenvironmental and drug effects on tumor growth
- Author
-
Jessica Kingsley, Ibrahim M. Chamseddine, Lisa J. McCawley, Aleksandra Karolak, Sharan Poonja, Katarzyna A. Rejniak, Shreya Mathur, and Dmitry A. Markov
- Subjects
Cancer Research ,Tumor microenvironment ,In silico ,Cell ,Cancer ,Biology ,medicine.disease ,Cell biology ,Extracellular matrix ,medicine.anatomical_structure ,Oncology ,In vivo ,Cell culture ,Organoid ,medicine - Abstract
In vivo tumor microenvironments are heterogeneous in their architecture, cellular contents, metabolic landscape, and extracellular matrix (ECM) composition. Moreover, these microenvironments can undergo temporal and spatial changes. This may alter tumor responses to anticancer therapies. To examine the complex and dynamic changes within tumors and in tumor microenvironments, we developed a computational single cell-based model of the three-dimensional multicellular organotypic cultures: Organoid3D. This model was calibrated to experimental data and reproduced growth dynamics and morphologies of four human breast cell lines: a nontumorigenic epithelial MCF-10A, a mildly tumorigenic MCF-10AT1, and metastatic MCF-10CA-1a and MCF-10CA-1d lines grown in various microenvironmental conditions. By explicitly including the fibril structure of the ECM in the model, we examined how ECM properties promote or suppress the growth of in silico tumor organoids. The quantitative integration of experimental data for organoids exposed to different concentrations of doxorubicin allowed us to derive hypotheses on relative importance of microenvironmental factors and chemotherapeutic treatments on organoid growth. Thus, the in silico organoid model interrogated with experimental data provides a tool for fast and broad hypotheses testing and presents an opportunity to explore experimental conditions beyond what is physically feasible in laboratory experiments. Citation Format: Katarzyna A. Rejniak, Sharan Poonja, Jessica Kingsley, Shreya Mathur, Ibrahim Chamseddine, Aleksandra Karolak, Dmitry A. Markov, Lisa J. McCawley. In silico organoids: A model for deconvolution of microenvironmental and drug effects on tumor growth [abstract]. In: Proceedings of the AACR Special Conference on the Evolving Landscape of Cancer Modeling; 2020 Mar 2-5; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2020;80(11 Suppl):Abstract nr A47. more...
- Published
- 2020
- Full Text
- View/download PDF
8. MA07.11 Survival Outcomes Based on Gender of Advanced Nonsmall Cell Lung Cancer Patients Treated with Pembrolizumab or Nivolumab in Everyday Clinical Practice
- Author
-
David Fenton, Leathia Fiorino, Doran Ksienski, Nicole S. Croteau, Sarah Irons, G. Geller, E. Brooks, Angela Chan, Elaine S. Wai, Ashley T. Freeman, Zia Poonja, and Mary Lesperance
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,Clinical Practice ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,Non small cell ,Pembrolizumab ,Nivolumab ,business - Published
- 2019
- Full Text
- View/download PDF
9. Comparative Evaluation of Micronuclei in Exfoliated Urothelial Cells in Patients with Smoking and Smokeless Tobacco-associated Lesions: A Prospective Quantitative Study
- Author
-
Janaki Subramanian Iyer and Leela Poonja
- Subjects
Oncology ,medicine.medical_specialty ,Smokeless tobacco ,business.industry ,Internal medicine ,Micronucleus test ,medicine ,In patient ,business ,Comparative evaluation - Abstract
ObjectiveTo clinically evaluate various tobacco-associated lesions and to evaluate and compare the micronucleus (MN) assay in exfoliated urothelial cells in patients with smoking and smokeless tobacco-associated lesions.Materials and MethodsThis study was conducted in the Department of Oral Pathology and Microbiology, Mahatma Gandhi Mission's Dental College and Hospital, Navi Mumbai, from October 2012 to June 2013. One hundred cases having tobacco habits (smoking or smokeless) and clinically detectable tobacco-associated lesions were included. Exfoliated urothelial cytosmears were prepared, stained with Papanicolaou and slides were scored for MN.ResultsAll cases (n = 100) were found to have tobaccoassociated lesions that were clinically detectable. Voided urine samples were collected from all cases (n = 100) who indulged in smoking and smokeless tobacco habit, with males (n = 71) and females (n = 29), whose ages ranged from 19 to 75 years. We observed that out of the 100 cases evaluated, 12 cases showed the presence of MN in the urine cytosmear. Of these 12 cases, n = 10 were bidi smokers and n = 2 were betel quid chewers. Owing to insufficient population of urothelial cells in the cytosmear, MN evaluation could not be statistically proved.ConclusionAlthough, MN score in the urothelial cells could not be statistically assessed, due to insufficient number of urothelial cells, our observations reveal that MN count seems to be increased in smokers than smokeless tobacco users. Thus, we urge the need for further studies to highlight the comparative evaluation of MN score between smokers and smokeless tobacco on urothelial cells.How to cite this articleIyer JS, Pathak J, Patel S, Poonja L, Swain N. Comparative Evaluation of Micronuclei in Exfoliated Urothelial Cells in Patients with Smoking and Smokeless Tobacco-associated Lesions: A Prospective Quantitative Study. J Contemp Dent 2015;5(2):93-97. more...
- Published
- 2015
- Full Text
- View/download PDF
10. Social media in cancer care
- Author
-
Rachel Adilman, Christine E. Simmons, Zia Poonja, and Yanchini Rajmohan
- Subjects
Locally advanced ,MEDLINE ,Breast Neoplasms ,Critical Care and Intensive Care Medicine ,Breast cancer ,Patient Education as Topic ,Nursing ,medicine ,Humans ,Social media ,Cooperative Behavior ,Clinical care ,Neoplasm Staging ,Quality of Health Care ,Information Dissemination ,Oncology (nursing) ,business.industry ,Communication ,Cancer ,General Medicine ,medicine.disease ,Oncology ,Female ,Neoplasm staging ,Cooperative behavior ,business ,Social Media - Abstract
Purpose of review To examine the current data supporting use of social media in breast cancer clinical care. Recent findings Although opportunities to utilize social media to increase knowledge have been commonly seized, the opportunity to improve communication among clinicians is lagging. Locally advanced breast cancer (LABC) requires timely coordination of care among many specialists, and presents an excellent scenario for enhanced utilization of current IT strategies. Summary A systematic review was conducted to assess the use of social media to enhance breast cancer care. In addition, a Web-based search using common search engines and publicly available social media was conducted to determine the prevalence of information and networking pages aimed at patients and clinicians. Over 400 articles were retrieved; 81% focused on delivery of information or online support to patients, 17% focused on delivery of information to physicians, and 1% focused on the use of social media to improve collaboration among clinicians. Web searches retrieved millions of hits, with very few hits relating to improving collaboration among clinicians. Although there is significant potential to utilize current technologies to improve care for patients and improve connectedness among clinicians, most of the currently available technologies focus solely on the delivery of information. more...
- Published
- 2014
- Full Text
- View/download PDF
11. Real World Immunotherapy Response and Pulmonary Toxicity in Patients Treated with Chest Radiation Therapy
- Author
-
David Fenton, Leathia Fiorino, Daniel Glick, Elaine S. Wai, G. Geller, Doran Ksienski, E. Brooks, and Zia Poonja
- Subjects
Cancer Research ,medicine.medical_specialty ,Radiation ,Pulmonary toxicity ,business.industry ,medicine.medical_treatment ,Immunotherapy ,Radiation therapy ,Oncology ,medicine ,Radiology, Nuclear Medicine and imaging ,In patient ,Radiology ,business - Published
- 2018
- Full Text
- View/download PDF
12. Pembrolizumab (Pem) for advanced non-small cell lung cancer (aNSCLC): Efficacy and safety in everyday clinical practice
- Author
-
Nicole S. Croteau, Dave Fenton, Mary Lesperance, Ashley T. Freeman, Doran Ksienski, Zia Poonja, E. Brooks, G. Geller, Elaine S. Wai, Angela Chan, Leathia Fiorino, and Sarah Irons
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Pembrolizumab ,medicine.disease ,Clinical trial ,Clinical Practice ,Immune system ,Internal medicine ,Medicine ,Non small cell ,business ,Lung cancer ,Adverse effect - Abstract
e20506 Background: In clinical trials, Pem improves overall survival (OS) compared to chemotherapy in a subset of patients (pts) with aNSCLC. Immune related adverse events (irAE) have correlated with improved OS in some studies. We explored efficacy and safety of Pem in a provincial population. Methods: aNSCLC pts treated with Pem between 06/2015 and 08/2018 at BC Cancer were retrospectively identified. Kaplan-Meier curves of OS from initiation of Pem were plotted and multivariable analysis (MVA) was performed with Cox proportional hazard regression models. 3, 6, and 9 month landmark Kaplan-Meier analysis was performed and log-rank tests used to determine the association of irAE subtypes with OS. Multivariable logistic regression models for irAE within 3 months of Pem initiation were also fit. Results: Characteristics of the 190 pt cohort: median age 70y (41-91), ECOG PS 2/3 at start of Pem: 34.2%, squamous histology: 22.1%, EGFR mutation: 3.7%, brain (13.7%) or liver (8.9%) metastases, PD-L1 expression ≥ 50%: 92.6%, treatment line: 1st/ ≥2nd: 74.2%/25.8%. Median cycles delivered 7 (range 1-35). With median survival follow-up of 6.1 months (range 0.03-39.8 months) and 43% pts decreased, median OS of Pem in the 1st line and ≥2nd line settings were 24.3 months (95% CI, 9.7-not reached, NR) and 13.4 months (95% CI, 8.1-NR), respectively. Pts with ECOG PS 2/3 had lower OS vs. ECOG PS 0/1 (5.8 months vs. 16.7 months, log-rank p < 0.0001). On MVA, only ECOG PS (p < 0.001) was associated with OS. 66 pts (34.7% of cohort) experienced 89 irAE; most common irAE: dermatitis (20pts), hypothyroidism (13pts), and pneumonitis (10pts). 8.4% of cohort developed grade 3 or 4 irAE; no grade 5 irAE. The odds of a grade ≥ 3 irAE within 3 months was 6.3 fold higher if ECOG 2/3 vs. 0/1 (p = 0.05). A weak association between pneumonitis and decreased OS at 9 month landmark (p = 0.09) was seen; otherwise no association with irAE subtypes at 3, 6, and 9 month landmarks was observed. Conclusions: In the whole cohort, clinical efficacy and toxicity of Pem was consistent with registration trials. Pts with ECOG PS 2/3 had a significantly lower OS and higher odds of developing grade ≥ 3 irAE than those with good ECOG PS 0/1. more...
- Published
- 2019
- Full Text
- View/download PDF
13. P1.01-50 Real World Experience of Nivolumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)
- Author
-
David Fenton, E. Brooks, Leathia Fiorino, G. Geller, Doran Ksienski, Mary Lesperance, Elaine S. Wai, Zia Poonja, D. Glick, and Nicole S. Croteau
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,In patient ,Non small cell ,Pembrolizumab ,business - Published
- 2018
- Full Text
- View/download PDF
14. P1.01-51 Real world Experience of Pembrolizumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)
- Author
-
D. Ksienski, E. Wai, M. Lesperance, N. Croteau, L. Fiorino, Z. Poonja, D. Fenton, G. Geller, E. Brooks, and D. Glick
- Subjects
Pulmonary and Respiratory Medicine ,Oncology - Published
- 2018
- Full Text
- View/download PDF
15. P1.01-24 Clinical Efficacy of Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients Treated with Prior Radiotherapy
- Author
-
D. Glick, Zia Poonja, Nicole S. Croteau, David Fenton, Mary Lesperance, Leathia Fiorino, Doran Ksienski, E. Brooks, G. Geller, and Elaine S. Wai
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Prior Radiotherapy ,business.industry ,medicine.medical_treatment ,Immunotherapy ,medicine.disease ,Internal medicine ,medicine ,Non small cell ,Clinical efficacy ,Lung cancer ,business - Published
- 2018
- Full Text
- View/download PDF
16. Localized prostate cancer presenting as a renal pseudo-tumour
- Author
-
Bernhard J. Eigl, Alan So, and Zia Poonja
- Subjects
Kidney ,Pathology ,medicine.medical_specialty ,Uropathy ,business.industry ,Genitourinary system ,Urology ,Case Report ,medicine.disease ,urologic and male genital diseases ,Prostate cancer ,medicine.anatomical_structure ,Ureter ,Oncology ,Prostate ,Medicine ,Ovarian tumours ,business ,Obstructive uropathy - Abstract
Malignant obstructive uropathy can be a result of common genitourinary malignancies (i.e., ureter, prostate, bladder, or kidney) or extrinsic processes, such as colon and ovarian tumours. We present a case of uropathy caused by prostatic obstruction, which initially presented as a renal psuedo-tumour. We also review the relevant literature. more...
- Published
- 2015
17. Do care pathways help us choose wisely in the setting of neoadjuvant therapy for breast cancer? Results of a pre-post analysis
- Author
-
Sheridan Wilson, Rachel Adilman, Christine E. Simmons, Stephen Chia, Zia Poonja, Dimas Yusuf, Robyn Leonard, and Yanchini Rajmohan
- Subjects
Oncology ,endocrine system ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,fungi ,medicine.disease ,Surgery ,Breast cancer ,Internal medicine ,Adjuvant therapy ,Medicine ,business ,Neoadjuvant therapy - Abstract
e17539 Background: Guidelines suggest that neoadjuvant therapy (NAT) should be an option for any breast cancer patient to whom adjuvant therapy would be offered. Studies show that those with aggres... more...
- Published
- 2015
- Full Text
- View/download PDF
18. An assessment of neoadjuvant therapy for breast cancer and treatment wait times at the BC Cancer Agency Vancouver
- Author
-
Christine Simmons, Rachel Adilman, Robyn Leonard, and Zia Poonja
- Subjects
Oncology ,endocrine system ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,fungi ,Cancer ,medicine.disease ,Inflammatory breast cancer ,body regions ,Breast cancer ,Nat ,Internal medicine ,Medicine ,In patient ,Hormone therapy ,skin and connective tissue diseases ,business ,Neoadjuvant therapy - Abstract
140 Background: Neoadjuvant therapy (NAT) is widely considered to be the standard of care for patients diagnosed with locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). NAT is also considered in patients with more aggressive subtypes (Her2+ or triple negative cancers). However, it remains unclear which patients are being considered for NAT, which patients are indeed receiving NAT, and how long the current wait times for chemotherapy and hormone therapy are in this patient population. This study was designed to characterize the breast cancer patients being referred to the BC Cancer Agency (BCCA) Vancouver’s NAT clinic, and to determine the average wait times for chemotherapy and hormone therapy in these patients. Methods: Between May 13th, 2013 and June 3rd, 2014, a total of 160 potential NAT candidates were seen at the BCCA Vancouver NAT clinic. Breast cancer characteristics and wait times for these patients were assessed prospectively using a secure database. Results: Of these 160 patients, 119 (74%) actually received NAT; 76.7% of these were deemed LABC patients (clinical stage IIB or III), and 6% were “window of opportunity” (WOP) patients (those considered for NAT due to long surgical wait times). NAT patient receptor status differed significantly from the receptor statuses of patients who did not receive NAT (p=0.006), with Her2+ and triple negative breast cancer patients being most likely to receive NAT. Seventy-eight percent of ER+Her2+, 86% of ER-Her2+, 67% of ER+Her2-, and 80% of triple negative patients received NAT. A total of 4 patients (2.5%) presented in clinic with metastatic disease and thus were not considered for NAT. The average wait time between when a patient was referred to the BCCA and when they commenced chemotherapy was 18.1 days (median: 16), while the average wait time to receive hormone therapy alone was 12.3 days (median: 10). Conclusions: These findings suggest a need to expedite screening and care for these high-risk breast cancer patients in order to characterize and treat the disease neoadjuvantly before it has metastasized. Strategies to reduce wait times in this breast cancer population are being further assessed. more...
- Published
- 2014
- Full Text
- View/download PDF
19. Social media use amongst oncologists: Results of a national physician survey
- Author
-
Christine E. Simmons, Caroline Chung, Zia Poonja, Yanchini Rajmohan, Martina Trinkaus, Rachel Adilman, E. Brooks, Robyn Leonard, Gloria Roldan Urgoiti, Madiha Naseem, and Nazik Hammad
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Cancer ,medicine.disease ,ComputingMethodologies_PATTERNRECOGNITION ,Oncology ,Nursing ,Physician survey ,Family medicine ,Medicine ,Social media ,business ,Healthcare providers - Abstract
e17519 Background: Cancer care requires coordinated and efficient communication from many healthcare providers. Web-based social media has the potential to improve cancer care by facilitating physi... more...
- Published
- 2014
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.